The H1 reports of Chinese listed companies in 2022 have all been revealed.

Stock price review: centralized procurement VS epidemic, differentiated growth and excess earnings. Two peaks in January 2022 and March-April 2022. IVD, low-value consumables, etc. performed prominently, mainly driven by the epidemic

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.

The use of biomarker and genetic tests during pregnancy is now extremely widespread. But what if both parents’ genes were broadly analyzed for possible risks prior to conception?

On September 1, Nanjing Vazyme Biotech Co.,Ltd. signed a strategic cooperation agreement with Henan Medical Biological Testing Company.

BGI Genomics said on Thursday that it has received CE-IVD marking for its next-generation sequencing-based test for thalassemia mutation detection.

Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.

Wanzijian medical testing is a medical diagnosis service section newly established by Orient Gene last year, as well as a key strategic layout section for Orient Gene to conduct industrial upgrading from “a product provider” to “a product provider + a third-party testing service provider”.

Biocartis on Thursday reported a 21 percent year-over-year increase in revenues for the first half of 2022 as higher collaboration revenue offset a decline in SARS-CoV-2 product sales.

SkylineDx said on Thursday that it has obtained CE-IVD marking for its Merlin Assay to predict which melanoma patients are at low risk of nodal metastasis.

On August 31, 2022, the signing ceremony of the agreement for strategic cooperation between Maccura and Siemens & PLM project initiation were held in Chengdu.

Burning Rock Biotech said Wednesday that its second quarter revenues were up about 3 percent year over year.

BioMérieux on Wednesday reported sales growth of approximately 5 percent for the first half of 2022 compared to the first half of 2021.

On August 30, Merck announced that the new indication for its nine-valent human papillomavirus vaccine (brewer's yeast) (hereinafter referred to as "nine-valent HPV vaccine") has been approved by National Medical Products Administration.

Thermo Fisher Scientific said on Tuesday that it has received CE-IVD marking for its Oncomine Dx Express Test, a next-generation sequencing tumor mutation profiling test, and the companion Oncomine Reporter Dx analysis software and has launched them.